BiotechTube
Invirsa

Invirsa

Cambridge, United States· Est.
invirsa.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Invirsa is a private, clinical-stage biotech leveraging a novel DNA damage response (DDR) platform centered on its lead compound, INV-102. The company has secured significant non-dilutive funding from BARDA and is advancing parallel development for ocular chemical injury (a medical countermeasure) and the large commercial market of diabetic dry eye. With a completed Phase 2 trial and a seasoned leadership team, Invirsa is positioned to validate its platform across multiple indications with high unmet need.

OphthalmologyRespiratoryMedical Countermeasures

Technology Platform

A small molecule platform designed to augment the body's DNA Damage Response (DDR) through predictable, pulsatile activation of p53, which stabilizes cells, enhances DNA repair, and reduces secondary inflammation via NF-κB antagonism.

Opportunities

The BARDA partnership provides non-dilutive funding to validate INV-102's platform, de-risking development for the large commercial diabetic dry eye market.
Success in diabetic dry eye could enable rapid expansion into other high-value ophthalmology markets like diabetic macular edema, leveraging the same DDR mechanism.

Risk Factors

The novel DDR mechanism, while promising, remains unproven in late-stage trials for its lead indications.
The company faces significant commercial competition in the crowded dry eye disease market and is dependent on the continuation and successful execution of its key BARDA government contract.

Competitive Landscape

In diabetic dry eye, Invirsa faces competition from large pharma (e.g., Allergan/AbbVie, Novartis) with anti-inflammatory drugs (Restasis, Xiidra, Cequa) and newer agents, but aims to differentiate with a disease-modifying approach. For its DDR platform in ophthalmology, it appears to be first-in-class, with no direct competitors targeting p53 pulsatile activation for ocular surface disease.

More companies in Small Molecule Drugs →More companies in United States →